Nuclear Power and the Energy Crisis: Politics and the Atomic Industry
In: Springer eBook Collection
17 Ergebnisse
Sortierung:
In: Springer eBook Collection
In: The economic history review, Band a17, Heft 2, S. 95-102
ISSN: 1468-0289
In: The economic journal: the journal of the Royal Economic Society, Band 47, Heft Supplement_1, S. 490-491
ISSN: 1468-0297
In: The economic journal: the journal of the Royal Economic Society, Band 47, Heft Supplement_1, S. 477-478
ISSN: 1468-0297
In: The economic journal: the journal of the Royal Economic Society, Band 46, Heft Supplement_1, S. 311-313
ISSN: 1468-0297
In: The economic journal: the journal of the Royal Economic Society, Band 46, Heft Supplement_1, S. 310-311
ISSN: 1468-0297
In: The economic journal: the journal of the Royal Economic Society, Band 45, Heft Supplement_1, S. 143-145
ISSN: 1468-0297
In: The economic journal: the journal of the Royal Economic Society, Band 41, Heft Supplement_1, S. 292-311
ISSN: 1468-0297
In: The Economic Journal, Band 72, Heft 288, S. 933
In: The economic history review, Band 6, Heft 1, S. 131
ISSN: 1468-0289
In: The economic history review, Band 13, Heft 1/2, S. 126
ISSN: 1468-0289
In: The Economic Journal, Band 51, Heft 202/203, S. 291
As professionals concerned for people with dementia today and dedicated to finding more effective treatment and prevention for dementia tomorrow, we value our membership of the European Union (EU) and are deeply concerned by the prospect of the UK exiting. The EU has made dementia research a priority and has made substantial funds available for research that is driving faster, more effective clinical trials that are our best hope of finding a disease-modifying therapy. With its strong science and translational research base, the UK is making a considerable contribution to these studies.
BASE
Parkinson's disease is a complex heterogeneous disorder with urgent need for disease-modifying therapies. Progress in successful therapeutic approaches for PD will require an unprecedented level of collaboration. At a workshop hosted by Parkinson's UK and co-organized by Critical Path Institute's (C-Path) Coalition Against Major Diseases (CAMD) Consortiums, investigators from industry, academia, government and regulatory agencies agreed on the need for sharing of data to enable future success. Government agencies included EMA, FDA, NINDS/NIH and IMI (Innovative Medicines Initiative). Emerging discoveries in new biomarkers and genetic endophenotypes are contributing to our understanding of the underlying pathophysiology of PD. In parallel there is growing recognition that early intervention will be key for successful treatments aimed at disease modification. At present, there is a lack of a comprehensive understanding of disease progression and the many factors that contribute to disease progression heterogeneity. Novel therapeutic targets and trial designs that incorporate existing and new biomarkers to evaluate drug effects independently and in combination are required. The integration of robust clinical data sets is viewed as a powerful approach to hasten medical discovery and therapies, as is being realized across diverse disease conditions employing big data analytics for healthcare. The application of lessons learned from parallel efforts is critical to identify barriers and enable a viable path forward. A roadmap is presented for a regulatory, academic, industry and advocacy driven integrated initiative that aims to facilitate and streamline new drug trials and registrations in Parkinson's disease.
BASE
International audience ; The Dementias Platform UK Data Portal is a data repository facilitating access to data for 3 370 929 individuals in 42 cohorts. The Data Portal is an end-to-end data management solution providing a secure, fully auditable, remote access environment for the analysis of cohort data. All projects utilising the data are by default collaborations with the cohort research teams generating the data. The Data Portal uses UK Secure eResearch Platform infrastructure to provide three core utilities: data discovery, access, and analysis. These are delivered using a 7 layered architecture comprising: data ingestion, data curation, platform interoperability, data discovery, access brokerage, data analysis and knowledge preservation. Automated, streamlined, and standardised procedures reduce the administrative burden for all stakeholders, particularly for requests involving multiple independent datasets, where a single request may be forwarded to multiple data controllers. Researchers are provided with their own secure 'lab' using VMware which is accessed using two factor authentication. Over the last 2 years, 160 project proposals involving 579 individual cohort data access requests were received. These were received from 268 applicants spanning 72 institutions (56 academic, 13 commercial, 3 government) in 16 countries with 84 requests involving multiple cohorts. Projects are varied including multi-modal, machine learning, and Mendelian randomisation analyses. Data access is usually free at point of use although a small number of cohorts require a data access fee.
BASE